CN102048719A - 一种阿戈美拉汀药物组合物 - Google Patents
一种阿戈美拉汀药物组合物 Download PDFInfo
- Publication number
- CN102048719A CN102048719A CN2009100710758A CN200910071075A CN102048719A CN 102048719 A CN102048719 A CN 102048719A CN 2009100710758 A CN2009100710758 A CN 2009100710758A CN 200910071075 A CN200910071075 A CN 200910071075A CN 102048719 A CN102048719 A CN 102048719A
- Authority
- CN
- China
- Prior art keywords
- agomelatine
- pharmaceutical composition
- composition
- granulate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002629 agomelatine Drugs 0.000 title claims abstract description 40
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 108010010803 Gelatin Proteins 0.000 claims abstract description 7
- 229920000159 gelatin Polymers 0.000 claims abstract description 7
- 239000008273 gelatin Substances 0.000 claims abstract description 7
- 235000019322 gelatine Nutrition 0.000 claims abstract description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000007779 soft material Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 6
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229960003987 melatonin Drugs 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004560 pineal gland Anatomy 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 2
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000001419 Melatonin receptor Human genes 0.000 description 2
- 108050009605 Melatonin receptor Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- 229940097276 5-methoxytryptamine Drugs 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 description 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100710758A CN102048719A (zh) | 2009-11-02 | 2009-11-02 | 一种阿戈美拉汀药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100710758A CN102048719A (zh) | 2009-11-02 | 2009-11-02 | 一种阿戈美拉汀药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102048719A true CN102048719A (zh) | 2011-05-11 |
Family
ID=43953741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100710758A Pending CN102048719A (zh) | 2009-11-02 | 2009-11-02 | 一种阿戈美拉汀药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102048719A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579415A (zh) * | 2011-01-14 | 2012-07-18 | 成都康弘药业集团股份有限公司 | 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物 |
CN103251567A (zh) * | 2013-06-05 | 2013-08-21 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
JP2016536351A (ja) * | 2013-12-23 | 2016-11-24 | 天津泰普葯品科技▲発▼展有限公司 | 安定な結晶x形アゴメラチン錠剤およびその調製方法 |
CN106727375A (zh) * | 2016-12-21 | 2017-05-31 | 江苏豪森药业集团有限公司 | 阿戈美拉汀片剂及其制备方法 |
-
2009
- 2009-11-02 CN CN2009100710758A patent/CN102048719A/zh active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579415A (zh) * | 2011-01-14 | 2012-07-18 | 成都康弘药业集团股份有限公司 | 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物 |
CN103251567A (zh) * | 2013-06-05 | 2013-08-21 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
CN103251567B (zh) * | 2013-06-05 | 2014-03-12 | 重庆华森制药有限公司 | 一种阿戈美拉汀片剂及其制备方法 |
JP2016536351A (ja) * | 2013-12-23 | 2016-11-24 | 天津泰普葯品科技▲発▼展有限公司 | 安定な結晶x形アゴメラチン錠剤およびその調製方法 |
CN106727375A (zh) * | 2016-12-21 | 2017-05-31 | 江苏豪森药业集团有限公司 | 阿戈美拉汀片剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106176640B (zh) | 一种含枸橼酸托法替布的药物组合物及其制备方法 | |
CN102218050A (zh) | 一种治疗抑郁症的药物组合物 | |
CN105534933A (zh) | 一种沃替西汀口腔崩解片及其制备方法 | |
CN102048719A (zh) | 一种阿戈美拉汀药物组合物 | |
WO2009155757A1 (zh) | 含有巴戟天寡糖的药物组合物及其制备方法 | |
CN101991559B (zh) | 一种稳定的阿戈美拉汀胶囊药物组合物 | |
EP0759299A1 (en) | Potentiation of serotonin response | |
CN102085344B (zh) | 一种木香顺气缓释制剂及其制备方法 | |
KR20100106324A (ko) | 대추의 cAMP에 의해 제조되는 우울제 | |
CN102441019B (zh) | 一种中药菊花口含片 | |
CN101991561A (zh) | 氯桂丁胺组合物 | |
CN103705774A (zh) | 一种具有治疗抑郁症作用的复方组合物及其制备方法与应用 | |
CN108309980A (zh) | 一种抗结核的吡嗪酰胺药物组合物及其制备方法 | |
CN105410941A (zh) | 能增加骨密度和免疫力的祺然片保健食品及其制法 | |
CN106924270B (zh) | 一种含有奥利司他的具有减肥功能的药物组合物 | |
CN105777520A (zh) | 一种新型查尔酮化合物Chalcone-1203及其组合物、制备方法和应用 | |
JP2023542292A (ja) | イブプロフェン制御放出錠及びその調製方法 | |
CN108853044B (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN106389430B (zh) | 一种非洛地平硝酸异山梨酯复方缓释片及制备方法 | |
CN108403710A (zh) | 牛蒡苷在制备抗抑郁药物中的应用及抗抑郁药物 | |
CN1686514A (zh) | 治疗焦虑症、抑郁症的中药制剂及其生产方法 | |
CN105380917B (zh) | 一种盐酸普拉克索缓释片及其制备方法 | |
AU2021102577A4 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
CN102058869B (zh) | 一种木香顺气胃漂浮制剂及其制备方法 | |
CN106619618A (zh) | 一种缬沙坦药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: YAN JIE Effective date: 20120210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120210 Address after: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant after: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant before: Yan Jie |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110511 |